Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AZTR
AZTR logo

AZTR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Azitra Inc (AZTR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.220
1 Day change
-10.31%
52 Week Range
2.660
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Azitra Inc (AZTR) is not a good buy for a beginner, long-term investor at this time. The stock lacks strong positive technical signals, has no significant trading trends, and its financial performance is weak with declining metrics. Additionally, the recent financing news, while positive for the company's research initiatives, has not sustained its stock price momentum. Given the user's impatience and unwillingness to wait for optimal entry points, this stock does not align with their investment goals.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 53.89, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 0.232, with significant resistance at 0.338 and support at 0.125. Overall, the technical indicators suggest a neutral outlook.

Positive Catalysts

  • The company recently secured $31.4 million in financing to advance its skincare research programs, which initially led to a significant stock price surge.

Neutral/Negative Catalysts

  • The stock has experienced a consistent decline in price (-6.65% in regular trading and -1.91% post-market). Financial performance metrics such as net income, EPS, and gross margin have significantly deteriorated. Additionally, there are no significant hedge fund or insider trading trends.

Financial Performance

In Q4 2025, the company reported zero revenue growth, a net income drop of -6.67% YoY, a sharp EPS decline of -90.38% YoY, and a gross margin drop of -100%. These metrics indicate poor financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes are available for this stock.

Wall Street analysts forecast AZTR stock price to rise
Analyst Rating
0
Wall Street analysts forecast AZTR stock price to rise
Buy
Hold
Sell
0
Current: 0.242
sliders
Low
0
Averages
0
High
0
0
Current: 0.242
sliders
Low
0
Averages
0
High
0
Maxim
Buy
downgrade
$4
AI Analysis
2025-09-24
Reason
Maxim
Price Target
$4
AI Analysis
2025-09-24
downgrade
Buy
Reason
Maxim lowered the firm's price target on Azitra to $4 from split-adjusted $13.32 and keeps a Buy rating on the shares. The firm is citing its expectations of dilution in cutting its price target as the company addresses capital needs to advance ATR-12 and ATR-04 forward in clinical development, the analyst tells investors in a research note. Maxim adds however that Azitra's lead program ATR-12 in Netherton syndrome reported positive initial safety data in June, and if positive, its ongoing Phase 1 trial could be a key catalyst for shares.

People Also Watch